AstraZeneca's (AZN) PARP inhibitor, Lynparza, receives approval for treating ovarian cancer in Japan, following its label expansion in the United States.
Global markets largely echoed Wall Street's fortunes over last week.
This week the cancer space was abuzz with news of label expansion of Kyprolis, Lynparza and Kymriah and positive data readouts for Cabometyx and Keytruda.
Nektar's (NKTR) shares soar in a year's time on a robust pipeline including several study initiations, positive readouts and strategic collaborations.
Nektar (NKTR) impresses with a strong pipeline of early and late-stage candidates. The company makes a significant progress with its lead candidate, Onzeald, for advanced breast cancer in adults.
AstraZeneca (AZN) and Merck (MRK) announce approval of label expansion of ovarian cancer drug, Lynparza, to include HER2-/HR+ breast cancer with germline BRCA-mutation.
Global markets endured a volatile week, guided by opposing factors.
U.S. regulators have approved the first drug aimed at women with advanced breast cancer caused by an inherited flawed gene.
--LYNPARZA reduced the risk of disease progression or death by 42% compared to standard of care chemotherapy
AstraZeneca's (AZN) benralizumab receives approval in Europe as maintenance treatment for severe eosinophilic asthma under the trade name Fasenra.
Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.
In a relatively slow week, Allergan's (AGN) job cut announcement remained the key highlight while Pfizer's collaboration agreements with Sangamo and Arvinas were also in focus.
Stock Monitor: AstraZeneca Post Earnings Reporting
The Zacks Analyst Blog Highlights: Apple, Mastercard, 3M, AstraZeneca and Mondelez
Top Analyst Reports for Apple, Mastercard & 3M
Merck's (MRK) shares declined in 2017 against an increase witnessed by the large-cap pharma industry. It remains to be seen if the company regains momentum in 2018.
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
We take a look at the factors especially the focus on CAR-T therapy that led to the phenomenal growth in Juno Therapeutics (JUNO) share price in 2017.
Although it's been a relatively slow week, two acquisition deals were announced with Roche (RHHBY) saying it will acquire Ignyta while Mallinckrodt will buy Sucampo.